EDEN PRAIRIE, Minn.--(BUSINESS WIRE)--Feb. 5, 2015--
SurModics, Inc. (Nasdaq: SRDX), a leading provider of surface
modification and in vitro diagnostic technologies to the healthcare
industries, today announced that Gerald B. (Jerry) Fischer has retired
from the board of directors, effective immediately. Fischer is stepping
down for personal health reasons. Following Fischer’s retirement, the
SurModics board now consists of eight members, seven of whom are
independent. At present, the board does not intend to fill the vacancy
created as a result of Fischer’s retirement as it is the Company’s
intention to reduce the size of the Board over time.
Fischer, who joined the board in 2002, was the former president and
chief executive officer of the University of Minnesota Foundation.
During his time with SurModics, he served on the audit and corporate
governance and nominating committees and helped guide SurModics through
a number of significant milestones in the Company’s evolution.
“On behalf of our Board and the SurModics management team, we thank
Jerry for his outstanding service and longstanding commitment to the
Company,” stated Scott Ward, Chairman of the Board. “Jerry has been an
extraordinary Board member, and we greatly appreciate the leadership,
insight and financial expertise he has provided over the past 12 years.
We are grateful for his thoughtful guidance, and we wish him all the
best in the future.”
Gary Maharaj, SurModics’ chief executive officer, further added, “I have
enjoyed and benefited from Jerry's service to the Board. I will greatly
miss his collaborative leadership style, deeps insights and sage
About SurModics, Inc.
SurModics’ mission is to exceed our customers’ expectations and enhance
the well-being of patients by providing the world’s foremost, innovative
surface modification technologies and in vitro diagnostic
chemical components. The Company partners with the world’s leading and
emerging medical device, diagnostic and life science companies to
develop and commercialize innovative products designed to improve
patient diagnosis and treatment. Core offerings include surface
modification coating technologies that impart lubricity, prohealing, and
biocompatibility capabilities; and components for in vitro
diagnostic test kits and microarrays. SurModics is headquartered in Eden
Prairie, Minnesota. For more information about the Company, visit www.surmodics.com.
The content of SurModics’ website is not part of this press release or
part of any filings that the Company makes with the SEC.
Source: SurModics, Inc.
Andy LaFrence, 952-500-7000
Vice President of
Finance and Chief Financial Officer